BioLight Life Sciences Ltd.
Kiryat Atidim
Building 3, 5th Floor
Tel Aviv
6158101
Tel: 972-73-2753400
Fax: 972-73-2753401
Website: http://www.bio-light.co.il/
Email: biolight@bio-light.co.il
About BioLight Life Sciences Ltd.
We are an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome, or DES, and age-related macular degeneration, or AMD. Our current products and product candidates are designed to address a number of significant unmet medical needs of large and growing patient populations related to these ophthalmic conditions, by reducing patient non-compliance with drug therapy administration, improving efficacy and safety of treatment, offering better diagnosis and optimizing delivery of medications.YEAR FOUNDED:
2005
LEADERSHIP:
CEO: Suzana Nahum-Ziberberg
CFO: Itai Bar-Natan
CLINICAL TRIAL:
Please click here for clinical trial information.
4 articles about BioLight Life Sciences Ltd.
-
Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange
6/12/2023
BioLight a publicly traded company on the Tel Aviv Stock Exchange, specializing in investments in biomed companies focusing on eye diseases, announced that its subsidiary, Diagnostear has entered into a binding LOI for a merger agreement with a Canadian corporation that is expected to list its shares on the Canadian Securities Exchange.
-
BioLight Life Sciences Reports Successful Results In Phase I/IIa Clinical Trial For Glaucoma Insert
7/24/2017
-
BioLight Life Sciences's TeaRx Multi-Parameter Diagnostic Assays To Be Used In Dry Eye Syndrome Drug Trial
2/23/2017
-
BioLight Life Sciences Reports Successful Feasibility Clinical Study Results For The Detection Of Prostate Cancer With CellDetect Non-Invasive Test
7/26/2016